• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Walgreens Boots Alliance Inc. (Amendment)

    2/13/24 5:17:30 PM ET
    $WBA
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples
    Get the next $WBA alert in real time by email
    SC 13G/A 1 tv02250-walgreensbootsallian.htm SCHEDULE 13G/A walgreensbootsallianceinc

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Schedule 13G

    Under the Securities Exchange Act of 1934
    (Amendment No.: 10)*

    Name of issuer:  Walgreens Boots Alliance Inc

    Title of Class of Securities:  Common Stock

    CUSIP Number:  931427108

    Date of Event Which Requires Filing of this Statement: December 29, 2023

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☒ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

    (Continued on the following page(s))

     

     

    13G

    CUSIP No.:  931427108

    1.  NAME OF REPORTING PERSON
    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

    The Vanguard Group - 23-1945930

    2.  CHECK THE APPROPRIATE [LINE] IF A MEMBER OF A GROUP

    A. 

    B.  X

    3.  SEC USE ONLY

    4.  CITIZENSHIP OF PLACE OF ORGANIZATION

    Pennsylvania

    (For questions 5-8, report the number of shares beneficially owned by each reporting person with:)

    5.  SOLE VOTING POWER

    0

    6.  SHARED VOTING POWER

    946,507

    7.  SOLE DISPOSITIVE POWER

    79,938,353

    8.  SHARED DISPOSITIVE POWER

    3,199,855

    9.  AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    83,138,208

    10.  CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    N/A

    11.  PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

    9.62%

    12.  TYPE OF REPORTING PERSON

    IA

     

     

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Schedule 13G
    Under the Securities Act of 1934

    Item 1(a) - Name of Issuer:

    Walgreens Boots Alliance Inc

    Item 1(b) - Address of Issuer's Principal Executive Offices:

    108 Wilmot Road
    Deerfield, IL 60015

    Item 2(a) - Name of Person Filing:

    The Vanguard Group - 23-1945930

    Item 2(b) – Address of Principal Business Office or, if none, residence:

    100 Vanguard Blvd.
    Malvern, PA 19355

    Item 2(c) – Citizenship:

    Pennsylvania

    Item 2(d) - Title of Class of Securities:

    Common Stock

    Item 2(e) - CUSIP Number

    931427108

    Item 3 - Type of Filing:

    This statement is being filed pursuant to Rule 13d-1.  An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E).

    Item 4 - Ownership:

      (a) Amount Beneficially Owned:

      (b) Percent of Class:

     

     

    (c)  Number of shares as to which such person has:

    (i)  sole power to vote or direct to vote:  

    (ii)  shared power to vote or direct to vote:  

    (iii)  sole power to dispose of or to direct the disposition of:  

    (iv)  shared power to dispose or to direct the disposition of:  

    Comments:

    The responses to questions 5 through 9 and 11 on the cover page(s) are incorporated by reference into this Item 4.  

    Item 5 - Ownership of Five Percent or Less of a Class:

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ☐

    Item 6 - Ownership of More Than Five Percent on Behalf of Another Person:

    The Vanguard Group, Inc.'s clients, including investment companies registered under the Investment Company Act of 1940 and other managed accounts, have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the securities reported herein.

    No one other person's interest in the securities reported herein is more than 5%.

    Item 7 - Identification and Classification of the Subsidiary Which Acquired The Security Being Reported on by the Parent Holding Company:

    Not applicable

    Item 8 - Identification and Classification of Members of Group:

    Not applicable

    Item 9 - Notice of Dissolution of Group:

    Not applicable

    Item 10 - Certification:

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.

    Signature

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Date:  February 13, 2024

    By /s/ Ashley Grim
    Name: Ashley Grim
    Title:  Head of Global Fund Administration

    Get the next $WBA alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $WBA

    DatePrice TargetRatingAnalyst
    2/28/2025$11.00 → $9.00Hold → Sell
    Deutsche Bank
    2/26/2024$23.00Market Perform
    Leerink Partners
    2/20/2024Hold → Reduce
    HSBC Securities
    1/3/2024$21.00Underweight
    Barclays
    12/22/2023$27.00Hold
    HSBC Securities
    10/23/2023$27.00 → $30.00Neutral → Overweight
    JP Morgan
    7/3/2023$37.00 → $27.00Underweight
    Morgan Stanley
    6/28/2023$46.00 → $34.00Buy → Hold
    Deutsche Bank
    More analyst ratings

    $WBA
    SEC Filings

    See more
    • Amendment: SEC Form SC 13E3/A filed by Walgreens Boots Alliance Inc.

      SC 13E3/A - Walgreens Boots Alliance, Inc. (0001618921) (Subject)

      7/11/25 4:34:10 PM ET
      $WBA
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples
    • SEC Form 8-K filed by Walgreens Boots Alliance Inc.

      8-K - Walgreens Boots Alliance, Inc. (0001618921) (Filer)

      7/11/25 4:30:33 PM ET
      $WBA
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples
    • SEC Form DEFA14A filed by Walgreens Boots Alliance Inc.

      DEFA14A - Walgreens Boots Alliance, Inc. (0001618921) (Filer)

      7/3/25 7:02:47 AM ET
      $WBA
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples

    $WBA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Executive Chairman of Board Pessina Stefano sold $9,163,161 worth of shares (832,258 units at $11.01) and bought $9,163,161 worth of shares (832,258 units at $11.01), decreasing direct ownership by 56% to 657,308 units (SEC Form 4)

      4 - Walgreens Boots Alliance, Inc. (0001618921) (Issuer)

      4/29/25 8:49:21 PM ET
      $WBA
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples
    • Bhandari Inderpal S bought $54,150 worth of shares (3,000 units at $18.05) (SEC Form 4)

      4 - Walgreens Boots Alliance, Inc. (0001618921) (Issuer)

      4/15/24 5:45:26 PM ET
      $WBA
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples
    • Mahajan Manmohan bought $116,280 worth of shares (6,000 units at $19.38) (SEC Form 4)

      4 - Walgreens Boots Alliance, Inc. (0001618921) (Issuer)

      4/2/24 6:40:23 PM ET
      $WBA
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples

    $WBA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Walgreens Boots Alliance Shareholders Overwhelmingly Approve Transaction with Sycamore Partners

      Transaction expected to close in the third or fourth quarter of calendar year 2025 Walgreens Boots Alliance, Inc. (NASDAQ:WBA) (the "Company" or "WBA") today announced that at the Company's Special Meeting of Shareholders (the "Special Meeting"), WBA shareholders approved the previously announced acquisition of the Company by entities affiliated with Sycamore Partners Management, L.P. ("Sycamore"). According to the preliminary results, approximately 96% of votes cast at the Special Meeting by all shareholders were voted in favor of the merger agreement proposal. In addition, approximately 95% of the votes cast at the Special Meeting by unaffiliated shareholders were voted in favor of th

      7/11/25 9:59:00 AM ET
      $WBA
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples
    • Walgreens Boots Alliance Reports Fiscal 2025 Third Quarter Results

      Third quarter financial results Third quarter loss per share1 was $0.20 compared to earnings per share of $0.40 in the year-ago quarter. The decline in earnings per share was primarily driven by prior year after-tax gains related to fair value adjustments on variable prepaid forward derivatives and a partial sale of the Company's equity method investment in Cencora, and higher tax expense in the current quarter. Adjusted earnings per share (EPS)2 was $0.38 compared to adjusted EPS2 of $0.63 in the year-ago quarter. The decline in adjusted EPS2 was primarily driven by a higher adjusted effective tax rate2, higher incentive accruals, lower U.S. retail sales and lower equity earnings in

      6/26/25 7:00:00 AM ET
      $WBA
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples
    • Walgreens and KFF's Greater Than Campaign to Offer Free HIV/STD Testing in Stores on June 27

      More than 415 local health departments and community organizations mobilize across the country for largest-ever National HIV Testing Day event Walgreens and Greater Than HIV/STDs, a public information campaign from KFF, are joining with health departments and community organizations to provide free rapid HIV, syphilis and hepatitis C testing at more than 575 Walgreens stores on June 27 for the nation's largest National HIV Testing Day (NHTD) event. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250612760766/en/ With more than 415 local testing partners in nearly all states, Washington, D.C. and Puerto Rico, this year's activat

      6/12/25 9:00:00 AM ET
      $WBA
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples

    $WBA
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • September 12, 2023 - FDA Issues Warning Letters to Firms Marketing Unapproved Eye Products

      For Immediate Release: September 12, 2023 The U.S. Food and Drug Administration has issued warning letters to eight companies for manufacturing or marketing unapproved ophthalmic drug products in violation of federal law. These warning letters are part of the agency’s ongoing effort to protect Americans from potentially harmful ophthalmic products. Eye products addressed in the eight warning letters are illegal

      9/12/23 10:44:21 AM ET
      $WBA
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples

    $WBA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Huffines Robert Luther

      4 - Walgreens Boots Alliance, Inc. (0001618921) (Issuer)

      7/11/25 5:21:10 PM ET
      $WBA
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples
    • SEC Form 4 filed by Director Jarrett Valerie B

      4 - Walgreens Boots Alliance, Inc. (0001618921) (Issuer)

      7/11/25 5:19:48 PM ET
      $WBA
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples
    • SEC Form 4 filed by Director Lederer John Anthony

      4 - Walgreens Boots Alliance, Inc. (0001618921) (Issuer)

      7/11/25 5:15:15 PM ET
      $WBA
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples

    $WBA
    Financials

    Live finance-specific insights

    See more
    • Walgreens Boots Alliance Shareholders Overwhelmingly Approve Transaction with Sycamore Partners

      Transaction expected to close in the third or fourth quarter of calendar year 2025 Walgreens Boots Alliance, Inc. (NASDAQ:WBA) (the "Company" or "WBA") today announced that at the Company's Special Meeting of Shareholders (the "Special Meeting"), WBA shareholders approved the previously announced acquisition of the Company by entities affiliated with Sycamore Partners Management, L.P. ("Sycamore"). According to the preliminary results, approximately 96% of votes cast at the Special Meeting by all shareholders were voted in favor of the merger agreement proposal. In addition, approximately 95% of the votes cast at the Special Meeting by unaffiliated shareholders were voted in favor of th

      7/11/25 9:59:00 AM ET
      $WBA
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples
    • Walgreens Boots Alliance Reports Fiscal 2025 Third Quarter Results

      Third quarter financial results Third quarter loss per share1 was $0.20 compared to earnings per share of $0.40 in the year-ago quarter. The decline in earnings per share was primarily driven by prior year after-tax gains related to fair value adjustments on variable prepaid forward derivatives and a partial sale of the Company's equity method investment in Cencora, and higher tax expense in the current quarter. Adjusted earnings per share (EPS)2 was $0.38 compared to adjusted EPS2 of $0.63 in the year-ago quarter. The decline in adjusted EPS2 was primarily driven by a higher adjusted effective tax rate2, higher incentive accruals, lower U.S. retail sales and lower equity earnings in

      6/26/25 7:00:00 AM ET
      $WBA
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples
    • Walgreens Boots Alliance Reports Fiscal 2025 Second Quarter Results

      Second quarter financial results Second quarter loss per share1 was $3.30 compared to loss per share of $6.85 in the year-ago quarter. Second quarter results include $4.2 billion of non-cash impairment charges attributable to WBA, net of tax and non-controlling interest, related to goodwill, intangible and other long-lived assets primarily at U.S. Retail Pharmacy and VillageMD, and $1.0 billion of after-tax gains related to asset monetization activities. Adjusted earnings per share (EPS)2 was $0.63 compared to adjusted EPS2 of $1.20 in the year-ago quarter. The decline in adjusted EPS2 was primarily driven by prior year adjusted effective tax benefit2, lower U.S. retail sales and prior

      4/8/25 7:00:00 AM ET
      $WBA
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples

    $WBA
    Leadership Updates

    Live Leadership Updates

    See more
    • Walgreens Appoints Jason Stenta as SVP and Chief Commercial Officer

      Stenta will lead B2B commercial growth strategy as the company strengthens its role as the first choice for community pharmacy and health services in the U.S. Walgreens, an integrated healthcare, pharmacy and retail leader serving millions of customers and patients every day, today announced the appointment of Jason Stenta as SVP and chief commercial officer. In this new role, Stenta will lead the company's commercial growth strategy, driving development and commercialization of B2B healthcare services built on the company's core assets, and enhancing partnerships with payers, health system providers and life sciences companies. This press release features multimedia. View the full release

      10/7/24 8:00:00 AM ET
      $WBA
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples
    • Walgreens Appoints Two New Leaders to its Retail and Customer Experience Team

      Names Tracey Koller as Chief Merchandising Officer and Sharmila Sudhakar as Group Vice President and Head of Digital Commerce Walgreens, the leading independent retail pharmacy and healthcare provider, today announced two key leadership appointments: Tracey Koller, senior vice president and chief merchandising officer, and Sharmila Sudhakar, group vice president and head of Walgreens digital commerce. The company believes these new appointments will significantly contribute to its efforts with regard to the turnaround of the business as the company focuses on enhancing the front of store and omnichannel experience for its customers while driving in-store efficiencies. This press release

      8/16/24 9:00:00 AM ET
      $WBA
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples
    • Super Micro Computer Inc. to Join the Nasdaq-100 Index® Beginning July 22, 2024

      NEW YORK, July 12, 2024 (GLOBE NEWSWIRE) -- Nasdaq (NASDAQ:NDAQ) today announced that Super Micro Computer Inc. (NASDAQ:SMCI), will become a component of the Nasdaq-100 Index® (NASDAQ:NDX) and the Nasdaq-100 Equal Weighted™ Index (NASDAQ:NDXE) prior to market open on Monday, July 22, 2024. Super Micro Computer Inc. will replace Walgreens Boots Alliance Inc. (NASDAQ:WBA) in the Nasdaq-100 Index® and the Nasdaq-100 Equal Weighted Index. Walgreens Boots Alliance Inc. will also be removed from the Nasdaq-100 Ex-Tech Sector™ Index (NASDAQ:NDXX), the Nasdaq-100 ESG™ Index (NASDAQ:NDXESG), and the Nasdaq-100 Sustainable ESG Select™ Index (NASDAQ:NDXSES) on the same date. Super Micro Computer Inc

      7/12/24 8:00:00 PM ET
      $NDAQ
      $SMCI
      $WBA
      Investment Bankers/Brokers/Service
      Finance
      Computer Manufacturing
      Technology

    $WBA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Walgreens Boots Alliance downgraded by Deutsche Bank with a new price target

      Deutsche Bank downgraded Walgreens Boots Alliance from Hold to Sell and set a new price target of $9.00 from $11.00 previously

      2/28/25 7:36:45 AM ET
      $WBA
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples
    • Leerink Partners initiated coverage on Walgreens Boots Alliance with a new price target

      Leerink Partners initiated coverage of Walgreens Boots Alliance with a rating of Market Perform and set a new price target of $23.00

      2/26/24 8:28:07 AM ET
      $WBA
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples
    • Walgreens Boots Alliance downgraded by HSBC Securities

      HSBC Securities downgraded Walgreens Boots Alliance from Hold to Reduce

      2/20/24 10:23:30 AM ET
      $WBA
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples

    $WBA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Walgreens Boots Alliance Inc.

      SC 13G/A - Walgreens Boots Alliance, Inc. (0001618921) (Subject)

      10/18/24 12:45:41 PM ET
      $WBA
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples
    • Amendment: SEC Form SC 13D/A filed by Walgreens Boots Alliance Inc.

      SC 13D/A - Walgreens Boots Alliance, Inc. (0001618921) (Filed by)

      8/20/24 4:05:58 PM ET
      $WBA
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples
    • SEC Form SC 13G/A filed by Walgreens Boots Alliance Inc. (Amendment)

      SC 13G/A - Walgreens Boots Alliance, Inc. (0001618921) (Subject)

      2/13/24 5:17:30 PM ET
      $WBA
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples